<DOC>
	<DOCNO>NCT02922582</DOCNO>
	<brief_summary>This Phase 2 , randomize , single-blind , active-controlled dose-ranging study subject schedule undergo total knee arthroplasty ( TKA ) . Approximately 60 subject ( 15 per arm ) plan enrollment . Subjects randomize 1:1:1:1 ratio receive either DepoTXA 400 mg , DepoTXA 800 mg , DepoTXA 1200 mg , IV TXA ( CyklokapronÂ® 1 gram ) .</brief_summary>
	<brief_title>Study Local Administration DepoTXA Reduced Bleeding Subjects Undergoing TKA</brief_title>
	<detailed_description />
	<mesh_term>Tranexamic Acid</mesh_term>
	<criteria>1 . Scheduled undergo elective unilateral open TKA general , spinal , regional anesthesia . 2 . American Society Anesthesiology ( ASA ) physical status 1 , 2 , 3 . 3 . Female subject must surgically sterile ; least 2 year postmenopausal ; monogamous partner surgically sterile ; practice doublebarrier contraception ; practice abstinence ( must agree use doublebarrier contraception event sexual activity ) ; use insertable , injectable , transdermal , contraceptive approve FDA great 2 month prior screen commit use acceptable form birth control duration study 30 day completion study . 4 . Able provide inform consent , adhere study visit schedule , complete study assessment . 1 . Currently pregnant , nursing , plan become pregnant study within 1 month study drug administration . 2 . Planned concurrent surgical procedure ( e.g. , bilateral TKA ) . 3 . Prior open knee surgery ipsilateral knee . Prior arthroscopy permit . 4 . Subjects take medication know procoagulant effect ( e.g. , combination hormonal contraceptive , Factor IX complex concentrate antiinhibitor coagulant concentrate , alltrans retinoic acid ) . 5 . Contraindication hypersensitivity TXA . 6 . History thrombosis prior VTE . 7 . Known coagulopathy active intravascular clotting . 8 . Prior myocardial infarction . 9 . Prior cardiovascular accident ( stroke ) subarachnoid hemorrhage . 10 . History epilepsy . 11 . Presence intravascular stent . 12 . History impaired kidney function , chronic respiratory disease , rheumatoid arthritis , coagulopathy , loss sensation extremity . 13 . Renal insufficiency ( serum creatinine level &gt; 2 mg/dL ) . 14 . Anemia ( Hgb level &lt; 10 g/dL ) . 15 . Uncontrolled anxiety , psychiatric , neurological disorder might interfere study assessment . 16 . Acquired defective color vision . 17 . Malignancy last 2 year , exception nonmetastatic basal cell squamous cell carcinoma skin localize carcinoma situ cervix . 18 . Suspected known history drug alcohol abuse within previous year . 19 . Body weight &lt; 50 kg ( 110 pound ) body mass index &gt; 44 kg/m2 . 20 . Administration investigational drug within 30 day 5 elimination halflives investigational drug , whichever longer , prior study drug administration , plan administration another investigational product procedure subject 's participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>